Fennec Pharmaceuticals Inc. (FENC)

Inozyme Pharma Revenue

Fennec Pharmaceuticals had revenue of $8.75M in the quarter ending March 31, 2025, a decrease of -65.52%. This brings the company's revenue in the last twelve months to $30.91M, down -31.23% year-over-year. In the year 2024, Fennec Pharmaceuticals had annual revenue of $47.54M with 123.69% growth.

• Revenue (ttm): $30.91M
• Revenue Growth: -31.23%
• P/S Ratio: 8.20
• Revenue / Employee: $966,000
• Employees: 32
• Market Cap: 255.20M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	47.54M	26.29M	123.69%
Dec 31, 2023	21.25M	19.72M	1,284.50%
Dec 31, 2022	1.54M	-	-
Dec 31, 2021	-	-	-
Dec 31, 2020	170.00K	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.